STAT+: How $500 explains Republican health policy, and the GLP-1 Rx wave
The one health care policy Republicans agree on, and a look at how rural providers are approaching AI.
Read at source →Source
STAT News
Medicine, biotech, and health policy
Health · 728 articles · page 11 of 21 · fetched 7 minutes ago
Pennsylvania officials report state’s third death involving measles
A Pennsylvania woman has died from complications associated with measles, the third death in the state this year…
Read at source →
STAT+: GSK touts lung cancer data from two drugs
Late-stage results for Definium's LSD treatment, AstraZeneca breast cancer drug fails key trial, and more biotech news…
Read at source →
AdSponsoredSiguimi
Pure chronological social — no algorithm
See who you follow, newest first. Free to join. Posts that stay visible — not buried by an algo.
Join siguimi.com →
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in…
Read at source →
Pennsylvania records third measles-related death amid outbreak
RSV season approaches, a federal judge pauses AAP challenge of RFK J.r vaccine charges, and more health news
Read at source →
STAT+: Definium’s LSD therapy eased anxiety in second large trial
The first wave of biotechs is nearing regulatory approval for psychedelic therapies, a class of treatments that appear…
Read at source →
STAT+: What’s in a name? Novo looks to a rebrand
Novo Nordisk is now going by Novo, part of a rebrand that the company hopes can signal a more focused, competitive…
Read at source →
Opinion: Am I a hypocrite for loving football despite CTE?
Sportswriter and football fan Michael Arkush has known about CTE for years. But he increasingly feels uneasy about…
Read at source →
Opinion: Restoring public trust in science doesn’t have a simple solution. That’s OK
“Messaging can’t substitute for the relational infrastructure needed for building and sustaining trust,” write Michelle…
Read at source →
The GOP’s $50 billion rural health fund is coming up short, hospital leaders say
Hospital leaders were excited about the Rural Health Transformation Fund until they saw the fine print.
Read at source →
STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals…
Read at source →
STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit…
Read at source →
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’…
Read at source →
STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
An E.U. AG recommended annulling part of a directive that requires drugmakers to finance 80% of the costs of wastewater…
Read at source →
U.S. officials declare an end to record-setting cyclospora outbreak, but its origin is still unknown
The largest cyclospora food poisoning outbreak in U.S. history is over, U.S. health officials said, but questions…
Read at source →
Medicaid will let states use ‘tiers’ to determine medical frailty
New Medicaid rules use allow use of tiers to determine work exemptions. Advocates fear complex guidelines could cause…
Read at source →
STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
Novartis investors are stepping up scrutiny of the company's dealmaking after setbacks to drugs it acquired through…
Read at source →
STAT+: Cancer drug shortages keep disrupting patient care
Platinum chemotherapy's long-term effects, surprising heart failure drug failures, and more biotech news from The…
Read at source →
Boycott launched against American Diabetes Association includes journal
Trump's $500 Obamacare promise, childhood cancer treatment with long-term risks, and more health news
Read at source →
STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGs
A newly approved AI tool can scan EKGs for severe heart attacks and, the company says, for rarer patterns indicating…
Read at source →
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a…
Read at source →
Opinion: I’m a public health communications consultant. Pro-vaccine advocacy needs more fun
“Somewhere along the way, we forgot how to celebrate vaccines,” writes public health communications consultant Adam…
Read at source →
Opinion: I’m a thoracic surgeon in New York City. For many of my patients, Sept. 11 is still not over
“For thousands of families, the Sept. 11 attack did not end when the fires were extinguished. It simply changed form,”…
Read at source →
STAT+: Right before midterms, Trump dangles $500 refunds for select ACA enrollees
The legal basis for the $500 checks, and who would get them, isn't entirely clear.
Read at source →
Platinum-based chemotherapy in childhood causes mutations that age the liver
Platinum chemotherapy aged the liver cells of treated children, making them look more like adult liver cells and…
Read at source →
Why two promising heart drugs flopped and what’s next
This week on "The Readout LOUD" podcast: Two experimental drugs were heralded as the next era in heart disease…
Read at source →
STAT+: The gifts from pharma companies that keep on giving
There has been rancorous debate over doctors accepting free gifts and speaking fees from pharma companies. That doesn't…
Read at source →
STAT+: Can AI save rural health care?
Nominees for top federal health roles to face Congress, and Trump officials are betting on AI to help save rural health…
Read at source →
STAT+: FDA expands Bayer lung cancer drug approval
UniQure readout tests durability of benefits, an AI effort to manage heart failure, and more biotech news from The…
Read at source →STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall…
Read at source →STAT+: Cancer medicines remain in short supply across the U.S., survey finds
An ongoing shortage of cancer medications continues to force leading cancer centers around the U.S. to seek work-around…
Read at source →
Oz says ‘AI-based avatars’ can help rural communities. Some leaders disagree
Feds invest in AI for heart failure, vaccines and this year's midterms, and more health news from Morning Rounds
Read at source →
STAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readout
Before the end of September, UniQure is expected to report four-year results from the closely tracked clinical trial of…
Read at source →
STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
A Roivant lung disease drug has succeeded in a mid-stage study. But the drug’s origins are another fascinating aspect…
Read at source →
Opinion: John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill
“Nothing in the recent reporting about John Fetterman is medically surprising,” write Michael P.H. Stanley and Isaiah…
Read at source →
Trump officials say AI will help save rural health care. Some leaders in the field don’t believe it
Rural health care providers have struggled for years. The Trump administration is pointing to a cutting-edge, if…
Read at source →